At this years’ CARE at ACG program Dr. Rob Myers (University of Calgary) presented on liver disease. He discussed key news in hepatology from the past year, focusing the majority of his presentation on HCV. What follows are the points discussed on this topic from a Canadian perspective.
Promising HCV Therapies Dominate Liver Discussion: Important Questions Remain Unanswered
- A new era of HCV treatment is coming to Canada (cure rates > 90%, minimal toxicity, few pills/simple regimens).
- With a higher cure rate, we can anticipate more patients being treated. Having gastroenterologists in community practice and primary care physicians treat is necessary for managing the impact of increasing patient numbers and/or decisions on screening for baby boomers (see abstract 228 below).
- Some important questions remain unanswered: When will treatment become available? What is the cost? Who is paying? What will be the optimal regimen for patient subtypes/groups?
Related Abstracts from ACG 2013
ACG 2013 Abstract #38: Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated With High SVR Rates: Integrated Results From 4 Phase 3 Trials in HCV Genotype 1–6. Kowdley, et al.
ACG 2013 Abstract #39: Safety and Efficacy of Interferon-Free Regimens of ABT-450/r, ABT-267, ABT-333 +/- Ribavirin in Patients With Chronic HCV GTI Infection: Results From the Aviator Study. Kowdley, et al.
ACG 2013 Abstract #228: Effectiveness of Birth Cohort Screening for Hepatitis C: An Inner-City Experience. Olosunde, et al.
More exciting news to follow as well as further updates from AASLD 2013. The themes Dr. Myers discussed at ACG will be built out/discussed in more depth at the AASLD conference. One exciting late-breaking abstract that is scheduled to be presented is:
AASLD 2013 LBA #20: Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir, and PPI-668, With and Without Ribavirin, in Patients With HCV Genotype-1a Infection. Jacob P. Lalezari, et al.